Prostate, Phase I

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

Volunteers
Health Professionals

What is the purpose of this trial?

Evaluate the safety and tolerability of AMG 509 in adult participants and determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Daniel P. Petrylak

daniel.petrylak@yale.edu

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and of Urology; Chief, Genitourinary Oncology

Sub-Investigators

Last Updated
09/27/2024
Study HIC
#2000027706